Alembic Pharma Soars 6% On USFDA Nod For New Drug

Alembic Pharma jumped 6% during Tuesday’s trade on the BSE after the company said that it has received US Food & Drug Administration (USFDA) tentative approval for its abbreviated new drug application (ANDA) for Dabigatran Etexilate Capsules, 150 mg.

 “The tentative approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) PRADAXA Dabigatran Etexilate Mesylate Capsules, Eq to 150 mg base, Boehringer Ingelheim,” said Alembic Pharma in a BSE filing on Monday.

Alembic Pharma was trading at Rs 541.10, up by Rs 25 or 4.84% as at 1306 hours on Tuesday, on the BSE. The stock had hit an intraday high of Rs 545.

For Quick Trial – 8962000225 ✔
or mail us here:
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma